Artiva Biotherapeutics is leveraging GC LabCell’s cell therapy technology to target cancer, and has raised series A funding from backers including the latter.
US-based oncology drug developer Artiva Biotherapeutics launched on Friday with $78m in series A funding from investors including GC LabCell, the pharmaceutical company that also provided its cell therapy technology.
GC LabCell and sister company GC, the biotech and healthcare holding group formerly known as Green Cross Holdings, joined 5AM Ventures, VenBio Partners and RA Capital Management, which co-led the round, and Medivate Partners.
Artiva is working on cell therapies to treat haematologic cancers or solid tumours by utilising natural…
